These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 29445178

  • 21. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
    Mazzawi T, Hausken T, Hov JR, Valeur J, Sangnes DA, El-Salhy M, Gilja OH, Hatlebakk JG, Lied GA.
    Scand J Gastroenterol; 2019 Jun; 54(6):690-699. PubMed ID: 31190584
    [Abstract] [Full Text] [Related]

  • 22. Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
    Lahtinen P, Jalanka J, Hartikainen A, Mattila E, Hillilä M, Punkkinen J, Koskenpato J, Anttila VJ, Tillonen J, Satokari R, Arkkila P.
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1321-1331. PubMed ID: 32343000
    [Abstract] [Full Text] [Related]

  • 23. Sequential laxative-probiotic usage for treatment of irritable bowel syndrome: a novel method inspired by mathematical modelling of the microbiome.
    Li M, Xu R, Li YQ.
    Sci Rep; 2020 Nov 09; 10(1):19291. PubMed ID: 33168839
    [Abstract] [Full Text] [Related]

  • 24. Clinical study on sequential treatment of severe diarrhea irritable bowel syndrome with precision probiotic strains transplantation capsules, fecal microbiota transplantation capsules and live combined bacillus subtilis and enterococcus faecium capsules.
    Lv L, Ruan G, Ping Y, Cheng Y, Tian Y, Xiao Z, Zhao X, Chen D, Wei Y.
    Front Cell Infect Microbiol; 2022 Nov 09; 12():1025889. PubMed ID: 36250045
    [Abstract] [Full Text] [Related]

  • 25. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K.
    Clin Gastroenterol Hepatol; 2014 Jun 09; 12(6):953-9.e4. PubMed ID: 24315882
    [Abstract] [Full Text] [Related]

  • 26. Gas chromatography/mass spectrometry based metabolomic study in a murine model of irritable bowel syndrome.
    Yu LM, Zhao KJ, Wang SS, Wang X, Lu B.
    World J Gastroenterol; 2018 Feb 28; 24(8):894-904. PubMed ID: 29491683
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Oh JH, Jang YS, Kang D, Chang DK, Min YW.
    Nutrients; 2019 Nov 27; 11(12):. PubMed ID: 31783597
    [Abstract] [Full Text] [Related]

  • 28. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.
    Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, Shamim S, Islam M.
    Eur J Gastroenterol Hepatol; 2014 Jun 27; 26(6):630-9. PubMed ID: 24722560
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial.
    Han K, Wang J, Seo JG, Kim H.
    J Gastroenterol; 2017 Apr 27; 52(4):432-443. PubMed ID: 27178566
    [Abstract] [Full Text] [Related]

  • 30. Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study.
    Yoon JY, Cha JM, Oh JK, Tan PL, Kim SH, Kwak MS, Jeon JW, Shin HP.
    Dig Dis Sci; 2018 Oct 27; 63(10):2754-2764. PubMed ID: 29876777
    [Abstract] [Full Text] [Related]

  • 31. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial.
    Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, Castellaneta S, Barone M, Indrio F, Gobbetti M, De Angelis M.
    J Clin Gastroenterol; 2019 Mar 27; 53(3):e117-e125. PubMed ID: 29688915
    [Abstract] [Full Text] [Related]

  • 32. The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study.
    Kurokawa S, Kishimoto T, Mizuno S, Masaoka T, Naganuma M, Liang KC, Kitazawa M, Nakashima M, Shindo C, Suda W, Hattori M, Kanai T, Mimura M.
    J Affect Disord; 2018 Aug 01; 235():506-512. PubMed ID: 29684865
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
    Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H.
    Neurogastroenterol Motil; 2015 May 01; 27(5):705-16. PubMed ID: 25809913
    [Abstract] [Full Text] [Related]

  • 34. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial.
    JanssenDuijghuijsen L, van den Belt M, Rijnaarts I, Vos P, Guillemet D, Witteman B, de Wit N.
    Eur J Nutr; 2024 Aug 01; 63(5):1983-1994. PubMed ID: 38653808
    [Abstract] [Full Text] [Related]

  • 35. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.
    Urgesi R, Casale C, Pistelli R, Rapaccini GL, de Vitis I.
    Eur Rev Med Pharmacol Sci; 2014 Aug 01; 18(9):1344-53. PubMed ID: 24867512
    [Abstract] [Full Text] [Related]

  • 36. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: Secondary endpoints of a double blind, randomized, placebo-controlled trial.
    Johnsen PH, Hilpüsch F, Valle PC, Goll R.
    EBioMedicine; 2020 Jan 01; 51():102562. PubMed ID: 31877418
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant].
    Gupta AK, Maity C.
    Medicine (Baltimore); 2021 Jan 22; 100(3):e23641. PubMed ID: 33545934
    [Abstract] [Full Text] [Related]

  • 38. Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
    Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T.
    Dig Dis Sci; 2018 Jul 22; 63(7):1890-1899. PubMed ID: 29777439
    [Abstract] [Full Text] [Related]

  • 39. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.
    Sisson G, Ayis S, Sherwood RA, Bjarnason I.
    Aliment Pharmacol Ther; 2014 Jul 22; 40(1):51-62. PubMed ID: 24815298
    [Abstract] [Full Text] [Related]

  • 40. The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation.
    Bai T, Xu Z, Xia P, Feng Y, Liu B, Liu H, Chen Y, Yan G, Lv B, Yan Z, Dai N, Long Y, Wei W, Shi Z, Li X, Fang X, Gao H, Qi L, Hou X.
    Am J Gastroenterol; 2023 Jul 01; 118(7):1256-1267. PubMed ID: 36717369
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.